



Novo Nordisk

seeks partners within

Diabetes
and protein delivery technologies



Novo Nordisk is a focused healthcare company

We are headquartered in Denmark and have affiliates in 80 countries.

Novo Nordisk is a worldwide market leader in diabetes with

- A full portfolio of insulin analogs
- The broadest portfolio of insulin delivery systems and a leading position in the global injection device market.

Novo Nordisk has a leading position in

- Hemophilia with inhibitors
- Growth hormone disorders
- Hormone replacement therapy.


Research and Development at Novo Nordisk

We are committed to research and development of new medicines that fulfil unmet medical needs and that are aligned with our therapy areas.

Our current research and development pipeline is focused on proteins and peptides within:

- Diabetes
- Hemophilia and hemostasis management
- Chronic inflammation and autoimmune diseases.

We bring proteins from molecule to market





Novo Nordisk seeks partnerships within Diabetes

Collaborations with universities, research institutes, and biotechnology companies play a key role in our R&D strategy. Novo Nordisk allocates approximately 20% of its research budget to external activities.

Our partnership focus within:

- **Diabetes**

- Insulins
- GLP-1s
- Therapeutic proteins and peptides targeting:
 - Insulin resistance
 - Insulin secretion
 - Glucose regulation via glucose dependent mechanisms
 - Glucose regulation and either obesity or hyperlipidemia/atherosclerosis
 - Beta cell regeneration, proliferation or neogenesis
 - Prevention and/or intervention of Type 1 or Type 2 diabetes
 - Inflammation related to diabetes
 - Obesity.

- **Protein technologies**

- Formulation
- Expression and production
- Engineering and modification
- Manufacturing.


- **Protein drug delivery systems (formulations and devices)**

- Injection/Infusion (needle, pump, syringe)
- Oral (including oral cavity, e.g. buccal and sublingual)
- Sustained (controlled) release
- Nasal (powder, liquid)
- Transdermal
- Needle-free injection.

Our pipeline in Diabetes

Our R&D pipeline demonstrates Novo Nordisk's commitment to improve treatment of both type 1 diabetes and type 2 diabetes. We have novel derivatives, analogs and formulations of insulin and GLP-1 in both pre-clinical and clinical development to provide a comprehensive portfolio of products for people with diabetes.





Contacts

Diabetes

Finn Bened Hansen, Corp. VP, e-mail: fbh@novonordisk.com



Diabetes, devices and delivery systems

Martin E. Judge, Sourcing Director, e-mail: meju@novonordisk.com



Diabetes, formulations and drug delivery technology

Tomas Landh, Sourcing Director, e-mail: tolh@novonordisk.com

